HIV Pre-Exposure Prophylaxis (PrEP) pharmaceutical Truvada was first-approved to treat HIV in 2004, and 15-years later received further approval by the FDA as a HIV-preventative measure. The biopharmaceutical company Gilead Sciences brought Truvada to market in PrEP form this year. Now, according to new data from government researchers, it has been revealed that the exorbitantly high cost of Truvada has resulted in only 20% of those who need it having received it.